Adalta Ltd has released a press release.
AD-214 well tolerated in Phase I extension study
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from AdAlta
- R&D tax refund received & R&D Loan repayment terms extended
- Prof Foley invited presentation AD-214
- Dosing simulations support AD-214 IV product profile
- AD-214 Phase I extension study fully enrolled
- AdAlta to Present at August 24th Virtual Investor Summit
Later from AdAlta
- Placement to raise up to $1.23million
- Oversubscribed placement result
- AdAlta closes oversubscribed $1.65 million raise
- AD-214 Phase I extension clinical study - interim results
- Chair address and CEO presentation to AGM
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta